Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Warns Decode Genetics of Potential Delisting

NEW YORK (GenomeWeb News) – Decode Genetics has received a letter from Nasdaq informing the firm that it currently does not comply with regulations regarding the market value of its stock.

The letter stated that for 10 consecutive trading days the market value of Decode's common stock has been below $50 million, the minimum level required for continued listing on the Nasdaq Global Market. The firm’s shares also do not comply with an alternative test set forth by a Nasdaq rule, which requires total assets and total revenue of $50 million each for the most recently completed fiscal year or two of the last three most recently completed fiscal years.   

If Decode does not regain compliance by Oct. 30, Nasdaq said that its shares would be delisted. If the company fails to meet the requirements for continued listing on the Nasdaq Global Market, it will consider whether to apply to transfer its common stock to the Nasdaq Capital Market.

Decode’s shares closed Friday at $.33.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.